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Abstract. There is inadequate understanding of the biology, pathology, transmission, and control of Plasmodium
vivax, the geographically most widespread cause of human malaria. During the last decades, study of this species was
neglected, in part due to the erroneous belief that it is intrinsically benign. In addition, many technical challenges in
culturing the parasite also hampered understanding its fundamental biology and molecular and cellular responses to
chemotherapeutics. Research on vivax malaria needs to be substantially expanded over the next decade to accelerate
its elimination and eradication. This article summarizes key knowledge gaps identified by researchers, national malaria
control programs, and other stakeholders assembled by the World Health Organization to develop strategies for con-
trolling and eliminating vivax malaria. The priorities presented in this article emerged in these technical discussions,
and were adopted by expert consensus of the authors. All involved understood the priority placed upon pragmatism
in this research agenda, that is, focus upon tools delivering better prevention, diagnosis, treatment, and surveillance
of P. vivax.
INTRODUCTION
Plasmodium vivax is the most geographically widespread
malaria parasite species and codominates with Plasmodium
falciparum as a cause of human malaria. Plasmodium vivax
infects tens of millions of people each year.1 Despite long
being regarded as benign, evidence now shows that P. vivax
is very often associated with severe, life-threatening, and fatal
malaria in patients from endemic areas as well as in travelers.2
Where control programs have been intensified in coendemic
areas, P. vivax tends to be more resilient than P. falciparum.3–5
This is due to biological features unique to P. vivax enhancing
its ability to survive in conditions unsuited to P. falciparum and
propagate further transmission.6 The conventional methods of
control historically aimed solely at P. falciparum may not suf-
fice. Interventions and strategies aimed specifically at P. vivax
would greatly accelerate progress against it.7
The following specific characteristics set P. vivax apart
from P. falciparum with respect to control and elimination:
1) the hypnozoite leads to relapses, repeated clinical attacks,
and onward transmission; 2) gametocytes emerge at an early
stage of infection, before onset of illness; 3) transmission
by a broad range of anopheline vector species residing in
diverse habitats and myriad distinct behaviors relevant to
transmitting the parasite; 4) more rapid development in the
vector in comparison to P. falciparum at the same tempera-
ture dampens the population effects of shortening mosquito
life span by insecticide-treated net (ITN) or indoor residual
spraying (IRS) interventions; and 5) shifts in vector species
and behaviors in response to use of long-lasting insecticidal
nets (LLINs) and IRS.8
To date, the only drug approved to eliminate the hypno-
zoite of P. vivax is primaquine (PQ). This drug sometimes
causes life-threatening acute hemolytic anemia in patients
with a deficiency in glucose-6-phosphate dehydrogenase
(G6PD). G6PD status is essential to safe treatment with
PQ, but that diagnosis is rarely available at the health
facilities where most malaria patients present. As currently
recommended by the World Health Organization (WHO),9
PQ requires a 14-day daily treatment course. Counseling
strict adherence carries the risk of serious harm in G6PD-
deficient patients. These factors, along with fear of PQ by
providers and patients alike, sharply erode the utilization
and therefore the effectiveness of PQ in practice. PQ is a
spectacularly inadequate and ineffective anti-infective drug.
Safer and more easily administered drugs are needed to
improve treatment of patients infected by P. vivax and enable
attacking the tenacious and harmful hypnozoite reservoir
residing in endemic communities virtually unmolested by any
intervention against it.
Scientific progress in P. vivax since 1960 has been minimal
compared with those in P. falciparum because P. vivax was
inappropriately regarded as a benign infection. Research on
P. falciparum was the priority because of its high mortality
and, in part, because it has been adapted to laboratory culti-
vation. In contrast, P. vivax cannot be maintained in in vitro
cultures, hindering fundamental research required to ade-
quately understand its biology, and advance the development
of vaccines and treatments.
Research on vivax malaria needs to be substantially
expanded over the next decade to address the priorities iden-
tified by researchers, national malaria control programs, and
other stakeholders. This article aims to summarize the main
knowledge gaps that are critical to P. vivax control and elimi-
nation. In particular, it focuses on the need to develop tools
and intervention strategies to achieve more effective preven-
tion, diagnosis, treatment, and surveillance of P. vivax.
BIOLOGY, CULTURE, AND DRUG SCREENING
Develop methods for continuous cultivation of P. vivax
in vitro. There is a need to collect, update, share new evidence,
and to coordinate research efforts to develop suitable in vitro
*Address correspondence to Quique Bassat, ISGlobal, Barcelona
Centre for International Health Research (CRESIB), Hospital
Clínic–Universitat de Barcelona, Rosselló 132, Barcelona E-08036,
Spain. E-mail: quique.bassat@isglobal.org
62
continuous culture protocols for the P. vivax liver stages and
for the continuous propagation of its blood stages.
Blood-stage culture of P. vivax. In vitro culture of
P. falciparum was first developed in 1976,10 but there are no
similar methods for continuous culture of P. vivax–infected
red blood cells (RBCs).11 To date, only short-term cultures
of P. vivax isolates have been achieved.12 Cryopreservation
for offsite processing and further studies of culture-adapted
P. vivax has been shown to be possible,13 but still requires
standardization and a wider replication. Success in short-term
cultivation of P. vivax blood stages have already provided
key insights into the drug susceptibility and the molecular
and cellular biology of this parasite.11–15 Long-term in vitro
culture of P. vivax would allow far broader access to labo-
ratory isolates and deeper understanding of the biology of
P. vivax, and facilitate the development of functional assays.
This step is critical in the development of drugs, vaccines,
new diagnostic tests, and to obtain gametocytes needed to
infect mosquitoes to provide sporozoites for investigation of
the liver stages.
Liver-stage culture of P. vivax. The main challenge in
P. vivax control and elimination is the inability to kill the
hypnozoite without the significant safety issues of adminis-
tering 8-aminoquinolines to patients with G6PD deficiency.
New and safer hypnozoitocidal therapies would represent an
enormous stride forward in eliminating P. vivax.
Screening of compounds for activity against hypnozoites
currently relies on an animal model (using the closely related
parasite, Plasmodium cynomolgi in rhesus monkeys). Recent
development has allowed drug compounds to be screened
using a P. cynomolgi liver-stage model.16 This in vitro assay
represents a major advance and significantly increases the
number of molecules that can be tested while substantially
reducing costs. In contrast to other such systems, this one
is capable of assessing hypnozoitocidal activity rather than
just causal prophylactic activity. In other words, it permits
assessing impacts upon hypnozoites by allowing their awak-
ening and maturation to active liver schizonts.
Efforts to refine these systems are underway in several
laboratories and ongoing challenges include finding stable
and receptive hepatocyte cell lines or a reliable source
of primary hepatocytes, securing a supply of viable sporo-
zoites (from patients, monkeys, or eventual blood-stage in
vitro culture).
A recently developed human liver-chimeric mouse model
shows promise both for screening drug candidates and for
elucidating hypnozoite biology, but is still relatively low
throughput due to expense.17
Investigate key steps in hypnozoite formation, metabolism,
and reactivation. There is no detailed knowledge of the biol-
ogy of P. vivax hypnozoites. It is unknown what determines
sporozoite development and differentiation into liver schiz-
onts versus hypnozoites. Several decades ago, Shute and
others conducted human challenge trials, the results of which
seemed to suggest that the process leading to hypnozoite dif-
ferentiation was genetically predetermined.18 There is also
no understanding of whether hypnozoites are metabolically
active during their dormancy period, or what triggers their
reactivation. Understanding these processes will be essen-
tial for developing both novel diagnostic markers that might
identify hypnozoite carriers and novel therapies that would
impede hypnozoite formation, eliminate the hypnozoite, or
trigger the reactivation of hypnozoites to make parasite stages
that are susceptible to available antimalarial drugs. The recent
development of a humanized mouse system with reactivating
hypnozoites17 as well as the development of P. vivax systems
biology resources should aid this endeavor.
Find important processes in the invasion of reticulocytes
and study infected RBC membrane structures. Plasmodium
vivax RBC invasion is a complex process which differs from
that of P. falciparum. After invasion, P. vivax actively remodels
the RBC membrane creating complex structures such as
caveola–vesicle complexes, which are thought to result in
the Schuffner’s dots visible on Giemsa-stained blood films.
The changes result in an extreme flexibility of the mem-
branes of P. vivax–infected RBCs. A better understanding of
how P. vivax invades reticulocytes, why it preferentially does
so (as opposed to infecting other more mature RBCs), and
how it remodels the RBC membrane after invasion would
facilitate the identification of novel vaccine candidate anti-
gens and potential drug targets.
Reexamine cytoadherent properties of P. vivax and their
potential role in avoiding spleen clearance. Much of the mor-
bidity and mortality associated with P. falciparum is due to
its ability to cytoadhere to endothelial cells, resulting in para-
site sequestration in small blood vessels and resultant organ
failure. Although P. vivax is known to adhere to vascular
endothelium, its capacity to do so is relatively limited com-
pared with P. falciparum,19 and little is known regarding the
mechanisms of P. vivax cythoadherence to those and other
human tissues. There is a need to better understand the role,
magnitude, and reversibility of such processes in P. vivax,
both in (severe) pathology and in the maintenance of chronic
P. vivax infections. A measure of the parasite sequestered
biomass (and location) in vivo is needed, and in particular,
P. vivax sequestration in organs like bone marrow and the
spleen. It has been hypothesized that the bulk of P. vivax
biomass may occur in those tissues compared with peripheral
blood,20 and some evidence supports that view.21
EPIDEMIOLOGY
Develop strategies to distinguish relapses from recrudes-
cence and reinfection. Current understanding of relapse pat-
terns of different vivax strains is mostly derived from either
experimental challenge or clinical studies in soldiers at war
in the Pacific carried out over 50 years ago, and these are
not likely to be repeated on any similar scale. To better
understand the epidemiology of P. vivax relapses,22 tools or
assay strategies that are able to distinguish between recru-
descence, new infection, and relapse are needed.23 Devel-
opment of such tools would facilitate assessment of drug
efficacy against P. vivax, help identify short- and long-latency
phenotypes within endemic areas, and pave the way towards
identifying hypnozoite diagnostic markers and triggers for
relapse. They would also lead to a better understanding of
the total disease burden due to relapse, which is likely to
have been greatly underestimated. Current strategies for
genotyping recurrent vivax infections rely mostly on micro-
satellite markers, and have revealed that relapses are often
multiclonal and usually heterologous (displaying a different
genotype compared with the preceding blood-stage infec-
tion in the same individual).24,25 The application of next-
generation sequencing technologies has the potential to shed
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more light on the genetic signatures of relapse (e.g., that
they are meiotic siblings)26,27 that maybe be exploited to
develop better genotyping methods.
In parallel, innovative epidemiological studies in well-
characterized clinical cohorts suffering relapse are extremely
useful to clarify the attributable fraction of relapse to new
infections, identify late recurrences, determine the efficacy of
antirelapse intervention, and study relapse biology in vivo.28
For example, further studies in persons returning to non-
endemic areas29 followed up for at least 6 months to 1 year,
have been conducted in the context of clinical trials of anti-
relapse therapies.
Explore the epidemiology of P. vivax transmission by
characterizing the infective reservoir and the contribution of
relapses to sustaining transmission. Current knowledge of
the epidemiology and dynamics of P. vivax transmission is
limited. Plasmodium vivax gametocytes develop earlier in
the blood-stage infection cycle and more rapidly than those
of P. falciparum and often appear before clinical symptoms.30
Plasmodium vivax gametocytemia tracks asexual parasitemia
closely. A small number of studies have shown that P. vivax
gametocytes are transmitted more efficiently to some anoph-
eline mosquito vectors than in P. falciparum, and P. vivax
gametocytes are transmissible at lower parasite densities.7
However, knowledge on the relationship between P. vivax
gametocyte density and infectivity to the mosquito is weak.
For example, in low-transmission settings, the majority of
P. vivax infections are asymptomatic and of low parasite den-
sity, and most of these infections carry gametocytes, but
the contribution of this feature to transmission in different
epidemiological settings is not well understood. There is a
need for further in-depth epidemiological, entomological,
and infectivity studies in different epidemiological settings to
better understand and target P. vivax transmission.
To date, few studies have successfully measured the rela-
tive contributions of new mosquito inoculations of P. vivax
sporozoites versus the activation of dormant hypnozoites to
the overall force of blood-stage infection.31 Ongoing studies
in Papua New Guinea, where P. vivax relapses earlier than
subtropical strains, indicate that relapses are responsible for
up to 80% of P. vivax blood infections and contributed
substantially to both clinical episodes and transmission.28,32
Other studies in Thailand and Papua, Indonesia, indicate
high prevalence of patent gametocytemia in relapsing infec-
tions, highlighting the importance of radical cure for reduc-
ing the transmission potential of P. vivax.33
A better understanding of the contribution of relapses to
the infectious reservoir and their importance for sustaining
transmission in areas with low transmission and/or long-
latency phenotypes is important for the development of
rational, evidence-based strategies for combatting and elimi-
nating endemic vivax malaria.
Investigate the pathophysiology of severe P. vivax malaria
and its associated global disease burden. Although long con-
sidered benign by malariologists and clinicians, the advent
of polymerase chain reaction (PCR) diagnostics in the clinic
beginning in the 1990s saw the emergence of a body of evi-
dence associating acute P. vivax with severe and fatal out-
comes. That evidence has been built into a compelling case
for discarding the “benign” label as misleading and danger-
ous, and instead viewing and managing vivax malaria as a
serious and life-threatening infection.2
It has been suggested that in settings where malaria is
endemic, inadequate therapy and repeated relapses are
important contributing factors for severe morbidity and
mortality with vivax malaria, particularly that of severe
anemia.21,34 Specific vulnerable groups, such as pregnant
women, have also been suggested to be at increased risk of
developing severe disease.35 Their fetuses are at a 4-fold
increase in risk of spontaneous abortion after even a single
clinical attack of P. vivax in the first trimester.36 Many
uncertainties still shadow our understanding of the mecha-
nisms through which P. vivax may trigger events leading to
severe and threatening illness in an as yet unknown pro-
portion of cases.
Further studies assessing the pathophysiology21,37 in vivo
or using postmortem samples38 will be required to better
understand the mechanisms related to severe disease, and
the role of cytoadhesion and other means of sequestration39
and/or inflammation in pathogenesis. The role of concomi-
tant infections and comorbidities in the development of
severe manifestations still needs to be elucidated.40
The WHO’s currently proposed working definition for
severe P. vivax malaria, derived from an expert review meet-
ing on severe malaria essentially states that “the criteria
for severe vivax malaria are the same as for adults and
children with severe falciparum malaria but with no para-
sitaemia density thresholds (and without the criterion of
hyperparasitaemia).2 A more specific expert consensus on
standards for case reporting, retrospective and prospective
hospital-based studies, and, importantly, village-based assess-
ments of morbidity and mortality by species should be
undertaken.2,20 Efforts should be made to carry out these
investigations across representative zones of endemicity.35
There is also a need to conduct studies to validate opti-
mal approaches for the management of patients with severe
P. vivax disease.40
Estimate the burden of P. vivax malaria in sub-Saharan
Africa. Duffy-negative phenotype in humans was believed to
confer complete protection against P. vivax blood-stage para-
sites, because of the generalized acceptance that parasites
could only invade the RBC using the Duffy receptor.41,42
Nevertheless, there is growing evidence supporting the pres-
ence of P. vivax infections among Duffy-negative popula-
tions in defined areas of sub-Saharan Africa in addition to
Madagascar and Mauritania.43,44 This suggests alternative retic-
ulocyte invasion pathways used by the species45 that should be
investigated and identified.
In addition, P. vivax associated with severe complications
has been reported from African countries.46–48 However, the
degree to which different populations living in sub-Saharan
Africa are affected by P. vivax malaria remains unknown.
The consistent finding of confirmed P. vivax in Europeans
traveling to west and central sub-Saharan Africa49 suggests
that endemic transmission occurs despite the overwhelming
dominance of Duffy negativity among residents. It may be
that endemic P. vivax indeed occurs but is not prevalent at
levels where it may be detected by routine means.
There is a need to estimate whether there is a significant
P. vivax burden in sub-Saharan African populations to deter-
mine whether appropriate screening, management, and sur-
veillance of P. vivax cases should be considered as part of
program activities, and if so, which diagnostic methods to
use for this screening.
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Map prevalence and severity of G6PD deficiency and
CYP2D6 poor metabolizers in endemic areas. The presence
of G6PD deficiency is a major operational obstacle to the imple-
mentation of antihypnozoite therapy with 8-aminoquinolines.
Countries have an increasing understanding of the prev-
alence and severity of the G6PD genotypes present in
their populations, but it is still inadequate to assess risk and
guide clinical and public health decision-making. Even less
is known about the prevalence of the trait among P. vivax
patients. As G6PD deficiency is known to be associated with
protection against malaria, including P. vivax,50 its preva-
lence in P. vivax patients is expected to be lower than in
the general population, thus altering the risk-benefit ratio
of 8-aminoquinoline therapy.51 A better understanding of
the geographical distribution of severe G6PD-deficiency
alleles in general and in P. vivax patients in particular
would assist development of evidence-based guidelines for
8-aminoquinoline therapy.
Information on G6PD genotypes, biochemical phenotypes,
and degree of hemolysis caused by PQ in specific endemic
areas will assist in the development of screening and treat-
ment strategies for PQ that mitigate the harm caused by the
drug or that of the parasite by withholding it, that is, repeated
clinical attacks originating as untreated hypnozoites.
PQ is a prodrug shown to be metabolized by the CYP2D6
isozyme of cytochrome P-450. People with specific CYP2D6
polymorphic alleles fail to metabolize PQ and may thus fail
treatment,52 leading to false assumptions of PQ tolerance in
the parasite. It is currently not clear to what degree CYP2D6
activity impairment may cause therapeutic failure against
hypnozoites (or gametocytes of P. falciparum as well) or
how common such CYP2D6 alleles may be among different
P. vivax–endemic areas. Better information on the CYP2D6–
PQ interaction in different P. vivax–endemic regions will
help understand the rates of PQ failures and help improve
the overall effectiveness of antirelapse therapy in realizing
crucial clinical and public health therapeutic objectives.
PREVENTION AND TRANSMISSION INTERRUPTION
Develop integrated vector control interventions that target
outdoor and early biting transmission and protect vulnerable
populations. A literature review identified 71 species/species
complexes of anopheline mosquitoes with the potential abil-
ity to transmit P. vivax.7 Many of these species are more exo-
philic and less anthropophilic than highly efficient vectors
such as the African vector species, An. gambiae. As such,
these species are less liable to conventional interventions
against themosquito vector, i.e., IRS and ITN (including LLIN).
Decades of vector control based on indoor insecticidal
strategies targeting endophilic mosquitoes have led to shifts
to greater outdoor and earlier biting behavior,† or shifts in
dominant vector species.‡ In addition, P. vivax seems to
develop more rapidly in the mosquito than P. falciparum,
thus limiting the efficacy of methods that aim at shortening
the mosquito lifespan, such as ITNs and IRS. As a conse-
quence, methods of control that are broadly more effective
in reducing P. falciparum transmission, such as ITNs, are less
successful in controlling P. vivax.54
New tools should be adapted to human and vector behav-
iors. In particular, the development of integrated vector
control interventions targeting outdoor and early biting
transmission before sleeping time is of high priority. Existing
tools need to be optimized (e.g., formulations of long-lasting
nonpyrethroid IRS), more appropriate delivery mechanisms
have to be devised and tested, and new or innovative control
methodologies involving biological and genetic approaches
have to be evaluated. These include, among others, safe,
novel, longer lasting, and reformulated synthetic insecticides;
insecticide-treated durable wall lining, plastic sheeting, and
other materials; topical and spatial repellents; insect growth
regulators such as pyriproxfen, attractive toxic sugar baits,
entomopathogenic fungi and other pathogens, and endosym-
bionts such as Wolbachia.55
New tools are needed to prevent P. vivax transmission,
especially in vulnerable and special at-risk groups such as
pregnant and lactating women, infants, or forest workers. In
fact, vector control tools may be the only available tools for
harm reduction among pregnant women and infants since
PQ is contraindicated in these two groups.
Strengthen entomological research by developing more
sensitive vector surveillance tools and standardizing proto-
cols for evaluating vector control interventions. More sensi-
tive vector surveillance tools—including the use of molecular
techniques—are needed to identify which vectors are truly
the primary vector species of P. vivax so that appropriate
and targeted control measures are taken. Well-designed
large-scale studies are needed to evaluate the impact of
vector control interventions, alone and in combination, in
areas where P. vivax is dominant. Standardized and univer-
sally acceptable protocols that specify the duration of study
follow-up, integration of epidemiological and entomological
analysis, quality control, and assay systems to determine vec-
tor behavior exposed to sublethal insecticide concentrations
are needed.
Develop a vaccine for P. vivax. Plasmodium vivax vaccine
development has been hampered by inadequate funding,
poor laboratory systems for evaluating potential vaccine
targets, few vaccine candidates, and very few clinical trials.
Each of these obstacles reflects the chronic neglect of
P. vivax as a research priority since 1960. In response, the
November 2013 update to the malaria vaccine technology
roadmap has for the first time included a call for new tools
to control and eliminate P. vivax. The updated malaria
†For example, Anopheles gambiae (Bioko Island, Kenya, Tanzania),
An. gambiae s.l. (Nigeria) and Anopheles funestus (Tanzania, Benin),
Anopheles farauti and Anopheles koliensis (Papua New Guinea,
Solomon Islands), Anopheles sinensis, Anopheles lesteri (syn.
Anopheles anthropophagus), and Anopheles minimus s.l. (China),
Anopheles dirus, Anopheles maculatus s.l., and Anopheles minimus s.l.
(Vietnam), An. dirus s.l. and An. minimus s.l. (Thailand, Vietnam),
Anopheles darlingi (Brazil, French Guiana, Guatemala), Anopheles
fluviatilis s.l. (Nepal).
‡For example, from Anopheles funestus to Anopheles gambiae s.l.
(Tanzania-Kenya border, Niger), from An. gambiae s.l. to Anopheles
arabiensis (Niger, Kenya, The Gambia, Tanzania) or Anopheles merus
(Pemba Island in Tanzania), from Anopheles koliensis and Anopheles
punctulatus to Anopheles farauti (Solomon Islands), from Anopheles
minimus to Anopheles harrisoni (Thailand, Vietnam), from Anopheles
lesteri to Anopheles sinensis (China), and from Anopheles darlingi to
Anopheles aquasalis (British Guiana).53
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vaccine technology roadmap§ strategy is to develop vaccines
to prevent both clinical disease and its transmission.
Disease-preventing vaccines offer the theoretical advan-
tage that vaccine-induced protective immunity might be
boosted by natural exposure to P. vivax and could there-
fore extend the duration of vaccine protection. On the
other hand, such vaccines may exacerbate the serious prob-
lem of asymptomatic carriers of infection that now seriously
impedes elimination in the low-transmission settings typical
of P. vivax endemicity. However, a transmission-blocking
vaccine, if widely applied in conjunction with other control
measures, could potentially more readily reduce transmis-
sion intensity and more substantially contribute to elimina-
tion success. In other words, such a product would prevent
both primary blood-stage infections and the establishment of
relapse-causing hypnozoites (in other people).
One approach for P. vivax disease prevention is to inter-
rupt merozoite invasion of RBCs via the critically important
ligand–receptor interaction between the P. vivax Duffy-
binding protein and the human RBC Duffy antigen. At the
time of writing, one of the P. vivax vaccine trials in the clini-
cal phase of development is based on this approach. How-
ever, the description of cases of P. vivax malaria among
Duffy antigen–negative individuals indicated that additional
parasite ligands (e.g., from the P. vivax reticulocyte-binding
protein family) might need to be concurrently targeted to
achieve an effective antibloodstage vaccine.
In addition, there are currently two ongoing clinical trials
based on the P. vivax circumsporozoite (CS) protein. Since
the CS protein is a malaria antigen involved in sporozoite
invasion of hepatocytes and also present on hypnozoites, it
is an attractive target against both the sporozoite and intra-
hepatic parasites.56
Vaccine development for preerythrocytic stages of P. vivax
has been hindered by difficulties conducting sporozoite chal-
lenge trials for P. vivax. These difficulties include the need
to obtain fresh wild-type isolates for each challenge, the
possibility of P. vivax relapses and the nonavailability of
radical cure with complete efficacy to prevent such relapses.
Only a few challenge trials have been conducted with lim-
ited success.
A Phase 1 safety and immunogenicity trial of a transmission-
blocking vaccine based on the sexual stage Pvs25 antigen
suffered from undesirable reactogenic side effects. A poten-
tially transformative effort for further development is under-
way to develop an in vitro assay of serum antibody–based
transmission blocking activity by showing that mosquitoes fed
on vaccinated individuals do not support the development of
P. vivax oocysts and sporozoites.
An as yet unfunded and unexplored avenue of vaccination
offers potential for success—vaccination by laboratory/factory-
reared sporozoites of P. falciparum cross-protecting against
infection of liver by sporozoites of P. vivax. The “live spo-
rozoite vaccine” technology has shown some efficacy with
P. falciparum,57,58 and some experiments and data suggest
cross-species protection may occur.59,60
Further development of P. vivax vaccines remains a prior-
ity as articulated in the updated malaria vaccine technol-
ogy roadmap. Any vaccine will also have to address the
high genetic diversity found in P. vivax, which is greater
than that found in P. falciparum61 and maintained even in
low-transmission settings. It may be that this area will only
move forward if significant new research and development
resources are obtained. Without this, the area is likely to
remain neglected.
CASE MANAGEMENT
Improve the evidence base for G6PD deficiency testing
and management and develop field-ready point-of-care tests
for detecting G6PD deficiency. Deficiency of G6PD is a
genetic trait widely distributed in populations across malaria-
endemic regions.62 Treatment with 8-aminoquinolines such
as PQ can trigger threatening acute hemolytic anemia in
patients with G6PD deficiency. Consequently, treatment of
P. vivax infection with 8-aminoquinolines should be under-
taken with knowledge of the individual’s G6PD activity sta-
tus. The use of PQ in pregnant women is contraindicated,
not because of the dangers it could cause on G6PD-deficient
pregnant women, but because of the uncertainty regarding
the G6PD status of the fetus.
At present, the use of a quantitative screening tool that
informs the relative degree of enzyme activity is the most
direct, accessible, and reliable approach, and remains the
gold standard for G6PD-deficiency assessment.63 Qualitative
tests are also available but only inform whether the person
has a certain high level of G6PD in his or her cells. These
tests are used as rapid screening tests but usually require a
confirmation testing using a quantitative test, with which the
actual amount of enzyme activity is measured. Genotyping
studies and enzyme activity assays can also be used; how-
ever, these methodologies have significant limitations such as
false negatives, high costs, or specialized equipment require-
ments.63 In general, however, these methods require fully
equipped laboratories and highly trained technical staff and,
as such, offer little utility for the vast majority of patients
suffering malaria in impoverished and often isolated rural
tropical settings.
Data on the performance of G6PD-deficiency-testing prod-
ucts is limited. A systematic evaluation of G6PD-deficiency-
testing products that are currently available should be carried
out in endemic settings to provide a comparative measure of
their performance in a standardized way and to distinguish
between adequate and poorly performing tests. Moreover,
there is a need to evaluate the effects of acute malaria on
G6PD tests, since G6PD-deficient patients who have recently
suffered hemolysis may have a normal G6PD test.
To improve G6PD-deficiency testing, further research
studies have to be conducted to determine the relationship
between G6PD genotype, the level of enzyme activity, and
the risk of hemolysis following different dosing regimens of
8-aminoquinolone antimalarials. Current qualitative tests for
G6PD deficiency have limitations in guiding treatment with
PQ in most heterozygous females.64 The phenomenon of
lyonization of this X-linked trait explains this problem, that
is, a variable proportion of RBCs will express mutant G6PD
and fully impaired enzyme activity. The clinical risk this
poses to females remains unknown.
Ultimately, there is a need for developing a rapid, inex-
pensive, and accurate point-of-care test for detecting G6PD
deficiency that can be used before PQ treatment in endemic§http://www.who.int/immunization/topics/malaria/vaccine_roadmap
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countries.1,63 This type of test should clearly distinguish the
enzyme activity above which it is safe to give therapeutic
doses of PQ.62,63 A point-of- care G6PD quantitative test
that functions as a combo test and also measures hemoglobin
level simultaneously should become available in 2016, includ-
ing a built-in thermometer to monitor optimum temperature
for the assay (Program for Appropriate Technology in Health-
GlaxoSmithKline; http://sites.path.org/dx/malaria/g6pd/). Such
a test will require evaluation under field conditions in ende-
mic areas.
Improve methods for defining antimalarial efficacy. In
areas with chloroquine-resistant P. vivax, artemisinin-based
combination therapies (ACTs) are recommended by the
WHO for the treatment of the acute attack.9 This offers a
unified ACT-based strategy for treating both P. falciparum
and P. vivax infections in regions where both species are
endemic. Unfortunately, current methods for defining anti-
malarial efficacy in P. vivax are more challenging than in
P. falciparum, due to the confounding effects of relapse epi-
sodes (see above). Also, while many molecular markers for
drug resistance have been described for P. falciparum, well-
defined genetic mutations that confer chloroquine resistance
in P. vivax remain elusive but represent an area of intense
study.65 Better methods for defining antimalarial efficacy are
required to be able to define when chloroquine or ACT effi-
cacy is compromised. Similar methods for measuring anti-
relapse efficacy of 8-aminoquinolines are also lacking but
critical for evaluating new hypnozoitocidal therapies.
Define the role of ACTs in P. vivax treatment. ACTs have
been adopted as the first-line therapy against P. vivax in a
handful of countries: Cambodia, Indonesia, Vanuatu, Solomon
Islands, and Papua New Guinea.66
However, more information is required regarding the effi-
cacy and safety of the different ACTs combined with PQ,
as well as the activity of PQ against relapse when com-
bined with ACTs instead of chloroquine.30,66 In addition,
cost-effectiveness analyses are required to compare ACTs
and chloroquine for vivax malaria and to assess the role of
these drugs in vivax malaria control and elimination efforts
at different transmission intensities.66
Learn how to administer PQ therapy safely and
effectively. The primary aim of the radical cure of P. vivax is
to ensure the elimination of both the acute blood-stage infec-
tion and the hepatic hypnozoites. This requires administra-
tion of two classes of therapies—blood schizontocidal and
hypnozoitocidal. Evidence on the efficacy of several widely
used PQ regimens is lacking, including those employing
ACT as partner drug in radical cure. Antirelapse clinical tri-
als are needed to optimize current policies and practices.1
For instance, assessment of short-course, high-dose PQ regi-
mens in studies with long follow-up period is crucial as
potential new strategies to improve patient’s adherence.1
Further studies are needed to define the risk benefit of PQ,
since both recurrent episodes of malaria and hemolytic reac-
tions from the drug can result in severe anemia. Evidence is
also needed regarding the total dose (which appears to be
the key determinant of efficacy) of PQ required to prevent
relapses, and this will need to be assessed in different geo-
graphical locations.1
In addition, data regarding the safety and efficacy of modi-
fied PQ regimens (e.g., weekly doses) for individuals with
G6PD deficiency are also required.
Develop guidelines for PQ use in children. Although PQ
pharmacokinetics have been partially characterized in studies
of healthy subjects and adult males with malaria, there are
few data available in young children, one of the most vul-
nerable populations at risk of recurrent episodes of vivax
malaria.67 However, a recent review of the literature reveals
11 clinical studies of PQ therapy that recruited patients
under 4 years of age. Although age-stratified tolerability was
not reported, the overall safety profile of PQ in G6PD nor-
mal individuals was excellent and no worse than for other
antimalarial drugs.67 Current WHO recommendations, issued
in 2015, have recognized this and now allow the use of PQ in
children older than 6 months.68
Still, more evidence is needed on the efficacy, safety and
pharmacokinetics of PQ in young children. The lack of
provision of radical cure for infants represents not only
a failure to reduce morbidity in this most vulnerable popu-
lation but also a lost opportunity to have an impact on
P. vivax transmission.1
Develop alternatives to 8-aminoquinolines. Tafenoquine,
an antimalarial drug invented by the U.S. Army over 30 years
ago, is currently the only alternative to PQ being developed
with proven efficacy against hypnozoites.69 Once licensed,
this drug will offer the enormous advantage of a single-dose
treatment against relapse. However, as an 8-aminoquinoline,
its use remains constrained to the knowledge of the G6PD
status of the individual to whom it needs to be administered,
similarly to PQ. Innovative G6PD diagnostic technologies
may greatly mitigate this problem and permit the full clinical
and public health benefits this new therapy promises. Devel-
opment of effective hypnozoitocidal drugs for preventing
P. vivax relapses and offering safety in G6PD-deficient
patients is a key research priority when considering malaria
elimination and eventual eradication. The use of drugs with
hypnozoitocidal activity will be crucial not only to prevent
relapses in infected patients but also to reduce P. vivax trans-
mission potential.
Develop strategies to prevent relapse in patients unable to
receive PQ. As explained, pregnant or lactating women,
their infants, and perhaps those diagnosed with G6PD defi-
ciency cannot receive PQ therapy. CYP2D6-impaired patients
may add further to this classification of patients. They require
alternatives to PQ as a means of preventing relapse. These
may include chemoprophylactic or chemopreventive strategies,
for example, intermittent preventive treatment of pregnant
women and infants in sub-Saharan Africa. Most of those
optimized and validated regimens, however, use sulfadoxine–
pyrimethamine, and these are ineffective against P. vivax.
The research community must conceive, evaluate, optimize,
and validate strategies for preventing relapse in patients
unable to receive PQ.
OPERATIONAL AND HEALTH SYSTEMS RESEARCH
Improve diagnostics for surveillance and elimination. A
large proportion of P. vivax infections are asymptomatic with
low and submicroscopic parasite densities.70 Studies should
assess the public health significance of subpatent P. vivax
infections,1 both in terms of chronic morbidity (e.g., anemia)
and their contribution to transmission (see above).
In the context of malaria elimination, new, affordable diag-
nostics that can rapidly and accurately diagnose low-density
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P. vivax infections are required to detect asymptomatic
parasite reservoirs resident in blood. Having a field-ready
(i.e., findings rendered within a time frame permitting
administration of therapy to those infected) diagnostic tool
to detect low levels of parasitemia will facilitate active case
detection and help monitor progress towards malaria elimi-
nation.71 PCR-based techniques have good analytical sensi-
tivity but are difficult to implement under field conditions,
whereas loop-mediated isothermal amplification (LAMP)
technology represents a more feasible method in resource-
limited field settings that still maintains good sensitivity to
detect Plasmodium parasites.72 Further research is needed
to assess the cost-effectiveness and implementation chal-
lenges of LAMP technology for pursuing active case detec-
tion in malaria-elimination settings. A serological diagnosis
of acute, subpatent, or latent malaria has not been ade-
quately explored. These technologies have for decades been
successfully applied to other infections difficult to diagnose
by demonstrating the agent or its DNA/RNA signature.
Develop strategies to target the hypnozoite reservoir. It
must be recognized that diagnostic tests based on the detec-
tion of blood-stage infections do not identify a significant
proportion of the reservoir of disease: carriers of the hypno-
zoite who show no outward signs of disease and who often
do not have blood-stage parasitemia. Diagnostic tests that
can either directly identify hypnozoite carriers or alterna-
tively identify people at high risk of recurrent parasitemia
(e.g., by identifying people with recent exposure to P. vivax)
would allow better identification and targeting of the infec-
tious reservoir which is key to transmission reduction.
Since there are currently no diagnostic methods that allow
the identification of individuals that harbor hypnozoites,
mass screening and treatment approaches are likely to be
ineffective against P. vivax since the hypnozoite reservoir
is undetected at the screening and therefore untreated.
Mass drug administration (MDA) with an 8-aminoquinoline–
containing regimen may thus be a more appropriate approach.
However, in low-transmission and preelimination settings,
most people may not carry hypnozoites. Given the risk of
hemolysis and the difficulty of implementing community-
wide G6PD testing, evidence to support alternative MDA
strategies is needed, for example, to target high-risk groups
(such as those working in endemic areas, travelers, or those
with confirmed recent exposure).
Evaluate the efficacy of current tools against P. vivax.
Improving the understanding of the efficacy, effectiveness,
cost-effectiveness, and appropriate mix of insecticide-treated
nets, preventive treatment, and/or IRS in vivax malaria
control is required. These interventions should be exam-
ined against endemic vivax malaria in context-specific set-
tings representative of the Americas, south Asia, southeast
Asia and the Pacific.
The relatively low transmission and thus large sample sizes
required for formal clinical trials makes direct evaluation
difficult and costly. Alternative approaches that combine in
silico prediction of efficacy using well-validated P. vivax
mathematical transmission models73 with careful evalua-
tion of programmatic implementation studies, may thus be
more cost-effective. This will, however, require further devel-
opment of P. vivax–transmission models, in particular of
models for low-transmission settings and the role of the
hypnozoite reservoir.
Improve access to antirelapse therapy. Given the key role
of P. vivax relapses, it is essential to improve access to anti-
relapse therapy for all P. vivax patients. In many areas, this
will not only require implementing evidence-based PQ regi-
mens but also the development approaches for facility-based
G6PD testing and/or monitoring for signs of hemolysis.
A high priority will be to conduct operational research
to optimize delivery of antirelapse therapy safely and effec-
tively in different settings including strategies to ensure adher-
ence to treatment.
Develop novel approaches to surveillance and optimize
strategies for detection of residual transmission “hot
spots.” As transmission ebbs to very low levels and becomes
geographically fragmented, the nature of surveillance sys-
tems needs to change. The focus shifts to the detection of
foci of residual transmission and different forms of reactive
surveillance (triggered by the detection of an index case)
should be adopted. At the same time, in those settings, the
surveillance strategies have to be used to direct the response.
In low-transmission areas or areas targeting elimination,
serological surveys of recent infection may be better suited
to the identification of P. vivax transmission foci than tradi-
tional mass-blood surveys that only detect current patent
infections. A different surveillance approach would be to
develop genotype maps of P. vivax infection at the district
level to better understand the local dynamics of P. vivax
transmission. A formal evaluation of different surveillance
approaches and their effectiveness in different epidemiologi-
cal settings is needed.
Use modeling to understand current status and future per-
spectives for vivax malaria. Epidemiological modeling can be
used to assess and quantitatively analyze the current state
of the P. vivax situation on a global and/or local scale. This
will assist in examining the probable impact and improved
targeting of interventions previously discussed. This may also
assist in optimizing the mix of interventions needed for the
interruption of transmission in P. vivax–endemic areas.74
CONCLUSIONS
Identifying the specific challenges to control and preven-
tion of P. vivax is of paramount importance to the global
fight against malaria. Without a special focus on vivax
malaria,75 local elimination will remain elusive and the tre-
mendously ambitious goal of malaria eradication will be
more costly, take longer, and its ultimate success less proba-
ble. In this respect, intense scientific research is required to
adequately address the many knowledge gaps that surround
this parasite species.
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